Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Ventripoint to Exhibit VMS+ 3.0 at the Canadian Society of Echocardiography 21st Annual Symposium

V.VPT

(TheNewswire)



Toronto, Ontario / TheNewswire / April 1, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that they are a proud sponsor of the 21st Annual Canadian Society of Echocardiography Annual Symposium and will be exhibiting the VMS+ 3.0 system.

The annual symposium is being held at the Toronto Marriott Downtown Eaton Centre Hotel from April 11th – 13th, 2019. It will explore aspects of interventional echocardiography and structural heart disease, the developing role of artificial intelligence in echo and cardiac imaging as well as a session on congenital heart disease.

“As one of the largest echo meetings in North America, we are looking forward to meeting with industry leading clinicians for a hands-on demonstration of the VMS+ 3.0. The compact and portable system can be set-up within minutes and fits seamlessly into the echocardiography workflow. This meeting will provide an excellent opportunity to showcase the system to our target demographic and aligns well with our strategic pre-launch plans,” commented Jessica Naman, Marketing Manager at Ventripoint Diagnostics.  

The VMS+ 3.0 system is designed to create 3D calculations for volumetric measurements and ejection fractions from standard 2D echo views for all four chambers of the heart with the of use Artificial Intelligence (AI).

The VMS+3.0 system is not commercially available for sale. For investigational use only.

About Ventripoint Diagnostics Ltd.

Ventripoint’s technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound.  The Company has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care.

For further information please contact:

Dr. George Adams, CEO, Telephone: (519) 803-6937

Email: gadams@ventripoint.com

Forward Looking Statements:

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Corporation can give no assurance that they will prove to be correct.  Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Other factors, which could materially affect such forward-looking information are described in the risk factors in the Corporation's most recent annual management’s discussion and analysis that is available on the Corporation’s profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Copyright (c) 2019 TheNewswire - All rights reserved.



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today